Search

Your search keyword '"Heptinstall, Jack"' showing total 6 results
Start Over Author "Heptinstall, Jack" Publication Type Magazines
6 results on '"Heptinstall, Jack"'

1. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Author

Edupuganti, Srilatha, Hurt, Christopher B, Stephenson, Kathryn E, Huang, Yunda, Paez, Carmen A, Yu, Chenchen, Yen, Catherine, Hanscom, Brett, He, Zonglin, Miner, Maurine D, Gamble, Theresa, Heptinstall, Jack, Seaton, Kelly E, Domin, Elizabeth, Lin, Bob C, McKee, Krisha, Doria-Rose, Nicole, Regenold, Stephanie, Spiegel, Hans, Anderson, Maija, McClosky, Nadia, Zhang, Lily, Piwowar-Manning, Estelle, Ackerman, Margaret E, Pensiero, Michael, Dye, Bonnie J, Landovitz, Raphael J, Mayer, Kenneth, Siegel, Marc, Sobieszczyk, Magdalena, Walsh, Stephen R, Gama, Lucio, Barouch, Dan H, Montefiori, David C, Tomaras, Georgia D, Ackerley, Cassie Grimsley, Graciaa, Daniel, Kelley, Colleen, Rouphael, Nadine, Curate-Ingram, Sharon, Korber, Bette, Wagh, Kshitij, Sane, Nandini, Grossman, Jennifer, Hasan, Sophie, Robinson, Michelle, Lucas, Jonathan, Gildea, Marianne, Babinec, Amber, Coomes, Bethany, Dumond, Julie, Beck, Justine, Chege, Wairimu, Han, Xue, Hanke, Jen, Karg, Carissa, Rinn, Laurie, Chicurel-Bayard, Miriam, Nagar, Shashikala, White, Hakeem, Cooley, W Scott, Broder, Gail, Hunt, Machel, Cummings, Vanessa, Donaty, Kristine, Randhawa, April, Fair, Ramey, Darden-Tabb, Noshima, Chaturvedi, Richa, Baden, Lindsey, Sherman, Amy, Gothing, Jon, Paz, Andres Avila, Klopfer, Julia, Powell, Megan, Piermattei, Anna, Heithoff, August, Weiner, Joshua A., Kovacikova, Gabriela, Axelrod, Katherine S., Zhang, Lu, Baral, Saman, Yates, Nicole, Chiong, Kelvin, Kuo, Irene, Jordan, Jeanne, Lintner, Madison, Langlands, Kayley, Saintilma, Bitana, Yellin, Hannah, Balachandran, Madhu, Magnus, Manya, Baumblatt, Jane, Tindale, India, Fortier, Samantha, Khodabakhshian, Aleen, Pierce, Nick, Gonzalez, Maricela, Mark, Lisa, Kuo, Melinda, and Afemata, Ste'von

Abstract

Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.LS and VRC07-523LS mAbs for safety and pharmacokinetics in adults.

Published
2025
Full Text
View/download PDF

2. The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy

Author

Jacobson, Jeffrey M., Felber, Barbara K., Chen, Huichao, Pavlakis, George N., Mullins, James I., De Rosa, Stephen C., Kuritzkes, Daniel R., Tomaras, Georgia D., Kinslow, Jennifer, Bao, Yajing, Olefsky, Maxine, Rosati, Margherita, Bear, Jenifer, Heptinstall, Jack R., Zhang, Lu, Sawant, Sheetal, Hannaman, Drew, Laird, Gregory M., Cyktor, Joshua C., Heath, Sonya L., Collier, Ann C., Koletar, Susan L., Taiwo, Babafemi O., Tebas, Pablo, Wohl, David A., Belaunzaran-Zamudio, Pablo F., McElrath, M. Juliana, and Landay, Alan L.

Published
2024
Full Text
View/download PDF

3. Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial

Author

Frank, Ian, Li, Shuying S, Grunenberg, Nicole, Overton, Edgar T, Robinson, Samuel T, Zheng, Hua, Seaton, Kelly E, Heptinstall, Jack R, Allen, Mary A, Mayer, Kenneth H, Culver, Daniel A, Keefer, Michael C, Edupuganti, Sri, Pensiero, Michael N, Mehra, Vijay L, De Rosa, Stephen C, Morris, Daryl E, Wang, Shixia, Seaman, Michael S, Montefiori, David C, Ferrari, Guido, Tomaras, Georgia D, Kublin, James G, Corey, Lawrence, and Lu, Shan

Abstract

An effective HIV vaccine will most likely need to have potent immunogenicity and broad cross-subtype coverage. The aim of the HIV Vaccine Trials Network (HVTN) 124 was to evaluate safety and immunogenicity of a unique polyvalent DNA–protein HIV vaccine with matching envelope (Env) immunogens.

Published
2024
Full Text
View/download PDF

4. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial

Author

Sobieszczyk, Magdalena E, Mannheimer, Sharon, Paez, Carmen A, Yu, Chenchen, Gamble, Theresa, Theodore, Deborah A, Chege, Wairimu, Yacovone, Margaret, Hanscom, Brett, Heptinstall, Jack, Seaton, Kelly E, Zhang, Lily, Miner, Maurine D, Eaton, Amanda, Weiner, Joshua A, Mayer, Kenneth, Kalams, Spyros, Stephenson, Kathryn, Julg, Boris, Caskey, Marina, Nussenzweig, Michel, Gama, Lucio, Barouch, Dan H, Ackerman, Margaret E, Tomaras, Georgia D, Huang, Yunda, and Montefiori, David

Abstract

Preclinical and clinical studies suggest that combinations of broadly neutralising antibodies (bnAbs) targeting different HIV envelope epitopes might be required for sufficient prevention of infection. We aimed to evaluate the dual and triple anti-HIV bnAb combinations of PGDM1400 (V2 Apex), PGT121 (V3 glycan), 10-1074 (V3 glycan), and VRC07-523LS (CD4 binding site).

Published
2023
Full Text
View/download PDF

5. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Author

Gilbert, Peter B., Huang, Yunda, deCamp, Allan C., Karuna, Shelly, Zhang, Yuanyuan, Magaret, Craig A., Giorgi, Elena E., Korber, Bette, Edlefsen, Paul T., Rossenkhan, Raabya, Juraska, Michal, Rudnicki, Erika, Kochar, Nidhi, Huang, Ying, Carpp, Lindsay N., Barouch, Dan H., Mkhize, Nonhlanhla N., Hermanus, Tandile, Kgagudi, Prudence, Bekker, Valerie, Kaldine, Haajira, Mapengo, Rutendo E., Eaton, Amanda, Domin, Elize, West, Carley, Feng, Wenhong, Tang, Haili, Seaton, Kelly E., Heptinstall, Jack, Brackett, Caroline, Chiong, Kelvin, Tomaras, Georgia D., Andrew, Philip, Mayer, Bryan T., Reeves, Daniel B., Sobieszczyk, Magdalena E., Garrett, Nigel, Sanchez, Jorge, Gay, Cynthia, Makhema, Joseph, Williamson, Carolyn, Mullins, James I., Hural, John, Cohen, Myron S., Corey, Lawrence, Montefiori, David C., and Morris, Lynn

Abstract

The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT80) biomarker—which quantifies the neutralization potency of antibodies in an individual’s serum against an HIV-1 isolate—can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT80of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT80<200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT80biomarker as a surrogate endpoint for evaluatinon of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines.

Published
2022
Full Text
View/download PDF

6. Immunologic detection of Giardia duodenalisin a specific pathogen–free captive olive baboon (Papio cynocephalus anubis) colony

Author

Saleh, Meriam N., Thomas, Jennifer E., Heptinstall, Jack R., Herbein, Joel F., Wolf, Roman F., Reichard, Mason V., and Zajac, Anne M.

Abstract

Several commercial Giardiaimmunoassays were evaluated in baboons for sensitivity and specificity as well as ease of use in a large specific pathogen–free (SPF) colony. An additional objective was to identify the assemblage(s) of Giardia duodenalispresent in this baboon colony. A direct immunofluorescent antibody test (IFAT) was used as the reference test. Tests evaluated were a patient-side rapid test for dogs and cats, a human rapid test, and a well-plate ELISA designed for use with humans. Test sensitivities and specificities were compared using the McNemar paired t-test and were further evaluated for agreement using an unweighted Cohen kappa statistic. When compared to the IFAT reference, both human tests were more sensitive than the veterinary test. Based on PCR and sequencing of the G. duodenalissmall-subunit ribosomal RNA and glutamate dehydrogenase loci, assemblage AI was present in this baboon colony. We found that 10 of the 110 (9%) baboons in this SPF colony were infected with a zoonotic strain of G. duodenalis.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results